Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CD69 | Q07108 | 2/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | PPARD | Q03181 | 2/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 5/20 | 0.32 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.32 |
| ▸ | PTPN6 | P29350 | 2/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2192012 | 0.95 | THRA (0.38) | THRATHRBSMN1; SMN2CD69ELANE | |
| SCHEMBL3452453 | 0.88 | THRB (0.40) | THRATHRBSMN1; SMN2CD69ELANE | |
| SCHEMBL3451321 | 0.88 | THRA (0.41) | THRATHRBSMN1; SMN2CD69ELANE | |
| SCHEMBL3451941 | 0.88 | THRA (0.39) | THRATHRBSMN1; SMN2CD69ELANE | |
| SCHEMBL12258191 | 0.86 | ESR1 (0.33) | ESR1ESR2RORC | |
| SCHEMBL3452510 | 0.86 | PTGDR2 (0.41) | THRATHRBCD69ELANE | |
| SCHEMBL3452257 | 0.86 | ELANE (0.36) | THRATHRBSMN1; SMN2CD69ELANE | |
| SCHEMBL13400794 | 0.85 | ESR1 (0.35) | ESR1ESR2RORCKMT2A | |
| SCHEMBL3453559 | 0.82 | CD69 (0.35) | THRATHRBSMN1; SMN2CD69ELANE | |
| SCHEMBL3452513 | 0.82 | THRA (0.42) | THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858819-B2 | Tris(formylphenyl) and novel polynuclear phenol derived therefrom | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-12-28 | — | — | US | disclosed |
| US-20100099908-A1 | TRIS(FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED THEREFROM | HONSHU CHEMICAL INDUSTRY CO., LTD. (JP) | 2010-04-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099908-A1 | TRIS(FORMYLPHENYL) AND NEW POLYNUCLEAR POLYPHENOL DERIVED THEREFROM | AS3MT, RRM2, SHROOM3 | THRA 1846/4885THRB 3036/4885SMN1; SMN2 2165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.